RET and medullary thyroid gland carcinoma: Notably, the EGFR A839T variant has been associated with response to gefitinib in lung cancer30, and the A876V variant of RET occurring in medullary thyroid carcinoma was found to lie within its catalytic loop, suggesting a possible aberration in kinase activity31, 32.